Seoul-based biotechnology company developing next-generation cancer immunotherapies, including ONCOKINE®, to address treatment resistance and refractory cancers
Seoul-based biotechnology company developing next-generation cancer immunotherapies, including ONCOKINE®, to address treatment resistance and refractory cancers. Its work includes immuno-oncology drug discovery, antibody therapeutics, target and biomarker discovery, precision medicine, and potential drug licensing or pharmaceutical partnerships.